# HSK41959 With Standard Therapy in Solid Tumors With MTAP Deletion

> **NCT07699757** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Haisco Pharmaceutical Group Co., Ltd.** · enrollment: 258 (estimated)

## Conditions studied

- Non-Small Cell Lung Cancer
- Pancreatic Ductal Adenocarcinoma (mPDAC)
- Advanced Solid Tumors

## Interventions

- **DRUG:** HSK41959
- **DRUG:** Sintilimab
- **DRUG:** Pemetrexed + Cisplatin /Carboplatin
- **DRUG:** Paclitaxel + Carboplatin
- **DRUG:** Nab-paclitaxel + Carboplatin
- **DRUG:** Nab-paclitaxel + Gemcitabine
- **DRUG:** Docetaxel

## Key facts

- **NCT ID:** NCT07699757
- **Lead sponsor:** Haisco Pharmaceutical Group Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-07
- **Primary completion:** 2029-04
- **Final completion:** 2029-11
- **Target enrollment:** 258 (ESTIMATED)
- **Last updated:** 2026-07-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07699757

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07699757, "HSK41959 With Standard Therapy in Solid Tumors With MTAP Deletion". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07699757. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*